The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12454
Abstract: Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B‐cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti‐cancer activity of ibrutinib against solid… read more here.
Keywords: ibrutinib; lung cancer; cancer; anti cancer ... See more keywords
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25662
Abstract: In this issue of the American Journal of Hematology Munir et al reported the final results of up to 6 years follow-up of the randomized RESONATE study, comparing the first-in-class Bruton Tirosin's kinase inhibitor (BTKi)… read more here.
Keywords: relapsed refractory; risk; ibrutinib; hematology ... See more keywords
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.2998
Abstract: To study the impact of dose modification and temporary interruption of ibrutinib in routine clinical practice, we conducted a retrospective study of consecutive CLL patients treated with ibrutinib outside the context of a clinical trial… read more here.
Keywords: dose modification; impact dose; interruption; ibrutinib ... See more keywords
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3470
Abstract: Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patients and performed… read more here.
Keywords: real world; ibrutinib; lymphocytic leukemia; bendamustine rituximab ... See more keywords
IL2-inducible T-cell kinase inhibitor ibrutinib reduces symptoms and Th2 differentiation in mouse allergic-rhinitis model.
Sign Up to like & getrecommendations! Published in 2021 at "Drug development research"
DOI: 10.1002/ddr.21884
Abstract: Th2 and Th17 immune response contribute to allergic rhinitis (AR) development. Targeting Th2 and Th17 response has been shown to ameliorate AR. Ibrutinib is an inhibitor for IL2-inducible T-cell kinase, which can promote Th2 and… read more here.
Keywords: allergic rhinitis; ibrutinib; model; th2 th17 ... See more keywords
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2695
Abstract: A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first‐in‐class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated… read more here.
Keywords: ibrutinib; lymphocytic leukemia; treatment; chronic lymphocytic ... See more keywords
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2723
Abstract: Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first‐in‐class, once‐daily inhibitor of Bruton's tyrosine kinase, an enzyme implicated in growth and survival of… read more here.
Keywords: phase; ibrutinib; carfilzomib dexamethasone; multiple myeloma ... See more keywords
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.2982
Abstract: The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar… read more here.
Keywords: use btk; ibrutinib; waldenstr macroglobulinemia; panel ... See more keywords
EBV‐MIR‐BHRF1‐1 TARGETS P53 GENE: POTENTIAL ROLE IN EPSTEIN‐BARR VIRUS ASSOCIATED CHRONIC LYMPHOCYTIC LEUKEMIA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.42_2631
Abstract: cell lines and paired ibrutinb resistant patients primary cells. Resistant MEC-1 cell line was cultured in RPMI 1640 without ibrutinib for 48hrs before transfection, siRNA targeting with PTBP1 mRNA and nontargeting siRNA were transfected into… read more here.
Keywords: mcl; cell line; ibrutinib; ptbp1 ... See more keywords
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04045-y
Abstract: Ibrutinib treatment has been shown to increase survival in patients with B cell malignancies. Real-life data suggest a large part of discontinuations are due to toxicities, impairing ibrutinib efficacy. We aimed to assess the impact… read more here.
Keywords: ibrutinib; pharmaceutical care; care program; treatment ... See more keywords
Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation
Sign Up to like & getrecommendations! Published in 2018 at "Inflammation"
DOI: 10.1007/s10753-018-0745-3
Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease with high mortality rate. The etiology is unknown and treatment choices are limited. Thus, there is great interest to investigate novel agents for IPF… read more here.
Keywords: bleomycin induced; ibrutinib; fibrosis; induced pulmonary ... See more keywords